IL145346A - Dimeric compounds and their use as inhibitors of neuraminidase - Google Patents

Dimeric compounds and their use as inhibitors of neuraminidase

Info

Publication number
IL145346A
IL145346A IL14534600A IL14534600A IL145346A IL 145346 A IL145346 A IL 145346A IL 14534600 A IL14534600 A IL 14534600A IL 14534600 A IL14534600 A IL 14534600A IL 145346 A IL145346 A IL 145346A
Authority
IL
Israel
Prior art keywords
neuraminidase
inhibitors
dimeric compounds
dimeric
compounds
Prior art date
Application number
IL14534600A
Other languages
English (en)
Other versions
IL145346A0 (en
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of IL145346A0 publication Critical patent/IL145346A0/xx
Publication of IL145346A publication Critical patent/IL145346A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL14534600A 1999-03-12 2000-03-09 Dimeric compounds and their use as inhibitors of neuraminidase IL145346A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP9139A AUPP913999A0 (en) 1999-03-12 1999-03-12 Novel chemical compounds and their use
PCT/AU2000/000165 WO2000055149A1 (en) 1999-03-12 2000-03-09 Dimeric compounds and as inhibitors of neuraminidase

Publications (2)

Publication Number Publication Date
IL145346A0 IL145346A0 (en) 2002-06-30
IL145346A true IL145346A (en) 2005-11-20

Family

ID=3813338

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14534600A IL145346A (en) 1999-03-12 2000-03-09 Dimeric compounds and their use as inhibitors of neuraminidase

Country Status (26)

Country Link
US (1) US6548476B1 (id)
EP (1) EP1165541B1 (id)
JP (1) JP5160000B2 (id)
KR (1) KR100805906B1 (id)
CN (1) CN1343205A (id)
AP (1) AP2001002277A0 (id)
AT (1) ATE295361T1 (id)
AU (2) AUPP913999A0 (id)
BR (1) BR0008939A (id)
CA (1) CA2367755C (id)
CZ (1) CZ20013274A3 (id)
DE (1) DE60020100T2 (id)
EA (1) EA200100968A1 (id)
ES (1) ES2241581T3 (id)
HK (1) HK1041693B (id)
HU (1) HUP0200190A3 (id)
ID (1) ID29868A (id)
IL (1) IL145346A (id)
MX (1) MXPA01009203A (id)
NO (1) NO327812B1 (id)
NZ (1) NZ514041A (id)
PL (1) PL350228A1 (id)
TR (1) TR200102794T2 (id)
TW (1) TWI268279B (id)
WO (1) WO2000055149A1 (id)
ZA (1) ZA200107450B (id)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732916C (en) * 1996-11-14 2002-06-06 Biota Scientific Management Pty Ltd Method and novel compounds for use therein
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US7157494B2 (en) * 2001-11-09 2007-01-02 Biota Scientific Management Pty. Ltd. Dimeric compounds and their use as anti-viral agents
AU2002336823B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AUPR879501A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2002340632B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AU2002340635B2 (en) * 2001-11-09 2008-03-13 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AUPR879401A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
ES2377318T3 (es) * 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
US7144450B2 (en) * 2004-12-04 2006-12-05 Xerox Corporation Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds
US7153349B2 (en) 2004-12-04 2006-12-26 Xerox Corporation Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7220300B2 (en) 2004-12-04 2007-05-22 Xerox Corporation Phase change inks containing bis(urea-urethane) compounds
US7317122B2 (en) 2004-12-04 2008-01-08 Xerox Corporation Curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7576235B2 (en) 2004-12-04 2009-08-18 Xerox Corporation Processes for preparing bis(urea-urethane) compounds
US7560587B2 (en) * 2004-12-04 2009-07-14 Xerox Corporation Bis[urea-urethane] compounds
US7314949B2 (en) 2004-12-04 2008-01-01 Xerox Corporation Trans-1,2-cyclohexane bis(urea-urethane) compounds
WO2008090151A1 (en) * 2007-01-23 2008-07-31 Therapicon Srl Antiviral compounds
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2009006613A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
WO2009006620A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
AU2008272854B2 (en) 2007-07-03 2014-03-13 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
AU2010295646B2 (en) * 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
NL2005389A (en) 2009-10-21 2011-04-26 Asml Netherlands Bv Lithographic apparatus, device manufacturing method, and method of applying a pattern to a substrate.
IT1396620B1 (it) * 2009-11-25 2012-12-14 Therapicon Srl Analoghi chimerici
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2609105B1 (en) * 2010-08-24 2016-03-09 Imperial Innovations Limited Glycodendrimers of polypropyletherimine
HK1200106A1 (en) * 2012-01-05 2015-07-31 阿拉维制药公司 Formulations for enhanced bioavailability of zanamivir
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
CN108473483B (zh) 2015-11-20 2022-08-30 奥斯维尔医疗私人有限公司 用于医药应用的化合物
RU2612221C1 (ru) * 2015-12-16 2017-03-03 Общество с ограниченной ответственностью "Синтавр" Блокаторы вируса гриппа
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN108003065B (zh) * 2016-10-27 2021-01-08 中国石油化工股份有限公司 一种具有增稠作用的化合物和润滑脂以及它们的制备方法
WO2018199798A1 (ru) * 2017-04-28 2018-11-01 Общество с ограниченной ответственностью "Синтавр" Пептидные производные противовирусного препарата занамивира
WO2018213933A1 (en) * 2017-05-25 2018-11-29 The Governors Of The University Of Alberta Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
CN111698999A (zh) * 2017-12-06 2020-09-22 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液
BR112021004266A2 (pt) 2018-09-06 2021-08-03 Cidara Therapeutics, Inc. conjugados, população de conjugados, composição farmacêutica e métodos para o tratamento de um sujeito com uma infecção viral e para o tratamento profilático
US20230056135A1 (en) * 2018-10-05 2023-02-23 Emory University Monomer and multimeric anti-hbv agents
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013079A1 (en) * 1990-02-27 1991-09-05 Drug Delivery System Institute, Ltd. Derivative of glycolipid containing sialic acid
EP0576592B1 (en) * 1991-03-18 2000-05-31 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
EP0638085A1 (en) * 1992-02-19 1995-02-15 The Biomembrane Institute Inhibition of cell adhesion by chemically-defined oligosaccharides, their derivatives, mimetics, and antibodies directed thereto
JPH0638784A (ja) * 1992-03-30 1994-02-15 Meiji Milk Prod Co Ltd シアル酸を構成要素とする糖鎖の製造方法
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
CN100409844C (zh) * 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
HU223099B1 (hu) 1996-03-01 2004-03-29 Biota Scientific Managemant Pty. Ltd. Eljárás influenzavírus kimutatására és az eljárásban alkalmazható vegyületek
US5891862A (en) * 1996-03-15 1999-04-06 Geltex Pharmaceuticals, Inc. Polyvalent polymers for the treatment of rotavirus infection
AUPO104396A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
WO1998003524A1 (fr) * 1996-07-23 1998-01-29 Seikagaku Corporation Nouveaux oligosaccharides a base de lactosamine et procede de preparation
AU732916C (en) 1996-11-14 2002-06-06 Biota Scientific Management Pty Ltd Method and novel compounds for use therein
JPH10182686A (ja) * 1996-12-26 1998-07-07 Ngk Insulators Ltd ガングリオシドＧＱ１ｂ類縁物質
WO1998046279A1 (fr) 1997-04-17 1998-10-22 Johnson & Johnson Medical Kabushiki Kaisha Feuilles indicateurs chimiques et poches pour sterilisation utilisant lesdites feuilles
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein

Also Published As

Publication number Publication date
MXPA01009203A (es) 2002-08-20
BR0008939A (pt) 2001-12-18
HK1041693B (en) 2005-10-14
HK1041693A1 (en) 2002-07-19
EP1165541A4 (en) 2002-06-05
US6548476B1 (en) 2003-04-15
ES2241581T3 (es) 2005-11-01
PL350228A1 (en) 2002-11-18
CN1343205A (zh) 2002-04-03
AP2001002277A0 (en) 2001-09-30
DE60020100T2 (de) 2006-01-19
JP5160000B2 (ja) 2013-03-13
NO327812B1 (no) 2009-09-28
EA200100968A1 (ru) 2002-02-28
TR200102794T2 (tr) 2002-09-23
AU2896600A (en) 2000-10-04
DE60020100D1 (de) 2005-06-16
NO20014409L (no) 2001-11-01
NO20014409D0 (no) 2001-09-11
EP1165541A1 (en) 2002-01-02
WO2000055149A1 (en) 2000-09-21
HUP0200190A3 (en) 2004-01-28
ZA200107450B (en) 2002-09-10
HUP0200190A2 (en) 2002-06-29
CA2367755C (en) 2007-08-28
NZ514041A (en) 2001-09-28
CA2367755A1 (en) 2000-09-21
ID29868A (id) 2001-10-18
KR20020005617A (ko) 2002-01-17
TWI268279B (en) 2006-12-11
AUPP913999A0 (en) 1999-04-01
IL145346A0 (en) 2002-06-30
KR100805906B1 (ko) 2008-02-21
JP2002539204A (ja) 2002-11-19
ATE295361T1 (de) 2005-05-15
CZ20013274A3 (cs) 2002-03-13
AU774222B2 (en) 2004-06-17
EP1165541B1 (en) 2005-05-11

Similar Documents

Publication Publication Date Title
IL145346A0 (en) Dimeric compounds and their use as inhibitors of neuraminidase
IL149118A0 (en) Inhibitors of neuraminidases
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
HUP0105113A3 (en) Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
NO20014858D0 (no) Anvendelse av CYP2D6 inhibitorer i kombinasjonsterapi
HUP0202251A3 (en) Heterocyclic containing biphenyl ap2 inhibitors and application
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
IL145907A0 (en) Use of glucosylceramide synthesis inhibitors in therapy
HUP0200391A3 (en) Use of pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
HUP0301005A3 (en) Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
ZA988469B (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
HUP0201925A3 (en) Cyclic peptide derivatives as inhibitors of integrin alphavbeta6 and their use
IL143987A0 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
IL131047A0 (en) Use of il-18 inhibitors
PL352200A1 (en) Inhibitors of viia agent
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
HUP0203139A3 (en) Imidazole derivatives as phosphodiesterase vii inhibitors and their use as pharmaceuticals
HRP20020970A2 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU7402201A (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU7608100A (en) 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees